首页> 外文期刊>Medical Physics >Setup verification and in vivo dosimetry during intraoperative radiation therapy (IORT) for prostate cancer.
【24h】

Setup verification and in vivo dosimetry during intraoperative radiation therapy (IORT) for prostate cancer.

机译:前列腺癌术中放疗(IORT)期间的设置验证和体内剂量测定。

获取原文
获取原文并翻译 | 示例
       

摘要

The purpose of this study was to check the setup and dose delivered to the patients during intraoperative electron beam radiation therapy (IORT) for prostate cancer. Twenty eight patients underwent IORT after radical prostatectomy for prostate cancer by means of a dedicated mobile accelerator, Novac7 (by Hitesys, SpA, Italy). A 9 MeV electron beam at high dose per pulse was used. Eighteen patients received IORT at escalating doses of 16, 18, and 20 Gy at 85% isodose, six patients for each dose level. Further, ten patients received 20 Gy at 85% isodose. The electron applicator position was checked in all cases by means of two orthogonal images obtained with brilliance intensifier. Target and organ at risk doses were measured in vivo by a MOSFETs dosimetry system. MOSFETs and microMOSFET dosimeters were inserted into sterile catheters and directly positioned into the rectal lumen, for ten patients, and into the bladder to urethra anastomosis, in the last 14 cases. Verification at 0 degree led to very fewadjustments of setup while verifications at 90 degrees often suggested to bring the applicator closer to the target. In vivo dosimetry showed an absorbed dose into the rectum wall < or =1% of the total dose. The average dose value inside the anastomosis, for the 12 patients analyzed, was 23.7 Gy with a standard deviation of +/-7.6%, when the prescription was 20 Gy at 85% isodose. Using a C-arm mobile image intensifier, it is possible to assess if the positioning is correct and safe. Radio-opaque clips and liquid were necessary to obtain good visible images. In vivo MOSFETs dosimetry is feasible and reliable. A satisfactory agreement between measured and expected doses was found.
机译:这项研究的目的是检查前列腺癌术中电子束放射治疗(IORT)期间向患者提供的设置和剂量。通过专用的移动加速器Novac7(Hitesys,SpA,Italy),对二十八位前列腺癌根治性前列腺切除术后的患者进行了IORT。每脉冲高剂量使用9 MeV电子束。 18名患者接受了剂量为16%,18 Gy和20 Gy的递增剂量IORT(等剂量为85%),每个剂量水平接受了6名患者。此外,十名患者接受了80 Gy的等剂量85%葡萄糖。在所有情况下,通过使用亮度增强器获得的两个正交图像检查电子施加器的位置。通过MOSFET剂量测定系统在体内测量处于危险剂量的靶标和器官。将MOSFET和microMOSFET剂量计插入无菌导管中,并直接放置在直肠内腔中,以治疗10名患者,最后14例放置在膀胱至尿道的吻合中。在0度进行验证几乎不会导致设置的调整,而在90度进行验证通常建议使涂药器更接近目标。体内剂量测定法显示直肠壁吸收剂量小于或等于总剂量的1%。当处方为20 Gy(等剂量为85%)时,对于12例分析的患者,在吻合术中的平均剂量值为23.7 Gy,标准偏差为+/- 7.6%。使用C型臂移动图像增强器,可以评估定位是否正确和安全。不透射线的夹子和液体是获得良好可见图像所必需的。体内MOSFET剂量测定是可行和可靠的。在测量剂量和预期剂量之间找到了令人满意的协议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号